Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Central Nervous System Diseases × tucatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Brain Neoplasms 2 Stomach Neoplasms 1 Neoplasm Metastasis 1 HER2-positive Metastatic Breast Cancer 1 Colorectal Neoplasms 1 Central Nervous System Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Trastuzumab 2 tucatinib 1 tipifarnib 1 pembrolizumab 1 glutathione pegylated liposomal doxorubicin 1 elacestrant 1 abemaciclib 1 Temozolomide 1 Rituximab 1 RAD1901 1 Cancer Vaccines 1 Bevacizumab 1 Adjuvants, Immunologic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04512261 2022-07-01

TOPAZ

Cedars-Sinai Medical Center

Phase 1/2 Withdrawn

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡